Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jacobio to Start Phase III Trial of Novel Combination in NSCLC with KRAS G12C Mutations

publication date: Feb 20, 2024

Jacobio Pharma was approved to start a China Phase III clinical trial of glecirasib, a KRAS G12C inhibitor, combined with the SHP2 inhibitor JAB-3312 as a first-line therapy for non-small cell lung cancer patients with KRAS G12C mutations. The company said JAB-3312 is the first SHP2 inhibitor to begin a Phase III study globally in combination with an KRAS G12C inhibitor. The combination will be compared to the current standard of care, a combination of an PD-1 antibody and chemotherapy. Jacobio, a Beijing-San Francisco biopharma, is developing the KRAS G12C inhibitor for several solid tumor cancers. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital